Tag Archives: C. difficile infection

9th Annual C. diff. Conference and Health EXPO Pushes Past COVID-19 and Embraces Virtual Technology to Provide Global Online Learning for Healthcare Professionals on Nov. 4-5

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO is honored to welcome over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia. World-renowned presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues from 10 a.m. - 4 p.m. ET on Nov. 4 - 5, 2021: 100% Live-online presentations, on-demand poster presentations, exhibitors, and real-time networking opportunities available. Conference registration is complimentary this year.

To learn more about this extraordinary conference, guest speakers, and the diverse topics being presented visit https://www.cdiff2021.com.

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO.

"The annual C Diff Foundation conference is a highlight of my learning year. The combination of academia, pharmaceutical, and governmental representation creates a learning environment that is second to none. I went initially in 2014 and have circled the conference dates on my calendar annually as immobile. The timing during C. difficile awareness month is tremendous as it summarizes all of the newest findings throughout the year," stated Paul Feuerstadt, MD, FACG, AGAF.

According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community.

C. difficile is one of the most common causes of health care- associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine). Based on internal estimates, the recurrence rate of two of the three antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and has a mortality rate of approximately 9.3%.

The C Diff Foundation expresses their gratitude to Seres Therapeutics for being the conference Diamond Sponsor. Seres Therapeutics, Inc. is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia, and graft-versus-host disease. For more information, please visit https://www.serestherapeutics.com.

Their gratitude is also extended to Ferring Pharmaceuticals for being the Platinum Sponsor of the 9th Annual International C. diff. Conference and Health EXPO. Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. For more information, please visit https://www.ferringusa.com.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient, caregiver, and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide. For more information: https://cdifffoundation.org/

Follow C Diff Foundation on Twitter @cdiffFoundation #cdiff2021 #cdiffawarenessmonth

C Diff Foundation(tm) is a trademark of C Diff Foundation, established 2012 in the U.S.

C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO is honored to welcome over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia. World-renowned presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues on Nov. 4 - 5, 2021.

Related link: https://cdifffoundation.org/

COVID Variants Do Not Stop C. diff. Awareness Walks Worldwide

TEANECK, N.J. /ScoopCloud/ -- C Diff Foundation announced today that the 5th Annual Global C. diff. Awareness Walks will take place on-demand, on a livestream, and in-person at Sims Park, New Port Richey, FL, and Brown Street Park Complex, Spring city, PA, and Milton A. Votee, Teaneck, NJ. This year's annual events will take place on Saturday, September 25, 2021, from 9 a.m. - 12 p.m. EDT. Learn more at: https://www.cdiffwalks.com

Proceeds from the events will benefit the C Diff Foundation's mission educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. During these unprecedented times the C Diff Foundation effectively adapts to overcome the many obstacles developing from this global virus and the variants of SARS-CoV-2 that have been emerging and circulating around the world throughout the COVID-19 pandemic.

C. diff. infections are one of the leading healthcare-associated infections facing local communities worldwide. According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C. diff., C. difficile), (formally known as Clostridium difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"C Diff Foundation volunteering members have a passion to improve the lives of patients, families, and caregivers who have been impacted by C. diff. infections worldwide," says Nancy C. Caralla, Founding President, Executive Director of the C Diff Foundation. "At the in-person C. diff. Awareness Walks, a safe distance will be maintained, and hand sanitizer will be available to ensure a safe outdoor event. 'Let's Walk' presents educational information shared by health care professionals, and C. diff. Survivors, through on-demand walks and livestream options located on the dedicated event website: https://cdiffwalks.com."

Thank you, Ferring Pharmaceuticals, for being the Global Sponsor of the 5th Annual Global C. diff. Awareness Walks. Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. For more information visit https://www.ferringusa.com.

We also extend our thanks to Seres Therapeutics, Inc. for being the Diamond Sponsor of the 5th Annual Global C. diff. Awareness Walks.

Seres Therapeutics, Inc. is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit https://www.serestherapeutics.com.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide. For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation

#cdiffwalks2021 #cdiff2021

C Diff Foundation(tm) is a trademark of C Diff Foundation, established 2012 in the U.S.

MEDIA CONTACT:

Kathy Bischoff, Global Walk Committee

kathy@cdifffoundation.org

(727) 205-3922

MULTIMEDIA:

IMAGE link for media: https://www.Send2Press.com/300dpi/21-0920s2p-cdf-events-300dpi.jpg

C Diff Foundation announced today that the 5th Annual Global C. diff. Awareness Walks will take place on-demand, on a livestream, and in-person at Sims Park, New Port Richey, FL, and Brown Street Park Complex, Spring city, PA, and Milton A. Votee, Teaneck, NJ. This year's annual events will take place on Saturday, September 25, 2021, from 9 a.m. - 12 p.m. EDT.

Related link: https://cdifffoundation.org/

C Diff Foundation with Leading Gastroenterologists Paul Feuerstadt, MD and Caterina Oneto, MD Announce Clinic Dedicated For C.difficile

HAMDEN, Conn. /ScoopCloud/ -- C Diff Foundation ( https://cdifffoundation.org/ ), a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization announced today that the Foundation will offer the first ever clinic sponsored by the C Diff Foundation and dedicated to patients diagnosed and recovering from a C. difficile infection (CDI).

The clinic will hold office hours beginning this month in Connecticut, which will be held on August 27, 2019 at the Gastroenterology Center of Connecticut (gastrocenter.org).

The second clinic will be held in November (date to be announced) at the Concorde Medical Group in Manhattan - New York City (www.concordemed.com). The clinic received an overwhelming response from patients in various stages of recovery, including 15 individuals already scheduled with multiple spots planned for patients with recently diagnosed infection or those who have had multiple episodes and need further guidance and management.

"We are delighted with the immediate and overwhelming response from the patient community. It is a testament to the needs of those suffering from this infection. With this clinic we hope to bring awareness, education and more importantly, cutting edge treatment to the general public," stated Dr. Feuerstadt.

There are plans for additional clinic dates next year in New York, Connecticut, Illinois and Minnesota.

Dr. Oneto said, "Through this clinic, we will provide access to high level care to a number of new consults, as well as existing patients, who are recovering from the infection. It is my pleasure to partner with the C Diff Foundation and lend my expertise to the management and hopefully, eradication of this debilitating disease."

"The clinics demonstrate Dr's Feuerstadt and Oneto's commitment over the many years raising C.diff. awareness while providing management of those suffering with a C.diff. infection for patients who might not otherwise be able to gain access to providers sub-specializing in caring for those with this infection. Their dedication resonates within the C.diff. community and we are grateful for their participation and support." stated Nancy Caralla, Founding President of the C Diff Foundation.

About C Diff Foundation

C Diff Foundation's mission is dedicated to reaching out to communities from villages to cities, to medical practitioners, medical students, C. diff. survivors, caregivers, and the patients combating a C. difficile infection (CDI) while providing the general public important information on prevention, treatments available, clinical trials in progress, and EPA registered products available for environmental safety worldwide.

About Paul Feuerstadt, MD

His areas of interest Clostridioides difficile infection (CDI) and ischemic diseases of the gut and in these areas he has presented his research extensively, authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt's is teaching, frequently giving lectures locally, regionally and nationally. He holds a clinical appointment as an Assistant Clinical Professor of Medicine at the Yale University School of Medicine and is a full-time attending physician at the Gastroenterology Center of Connecticut seeing patients with a broad spectrum of clinical gastroenterological diseases.

Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan for medical school and completed his residency in internal medicine at New York Presbyterian Hospital/Weill Cornell. His clinical fellowship training was completed at Montefiore Medical Center in the Bronx, New York.

About Caterina Oneto, MD

Dr. Caterina Oneto, MD is a Gastroenterologist in private practice in New York and is affiliated with NYU Langone. She completed her Fellowship in Gastroenterology at Montefiore Medical Center, Albert Einstein College of Medicine. Dr Oneto is Co-Director of Clinical trials at Concorde Medical Group. Her main focus is Irritable Bowel Disease (IBD),

Clostridioides difficile infections (AKA C.diff., C.difficile, CDI) and Microbiome modification. Dr Oneto is also Co-Director of the C.diff. Community Global Support program offered by the C Diff Foundation. Dr Oneto appears regularly on Doctor Radio on Sirius Xm and C.diff. Spores and More Radio (cdiffradio.com).

About C.difficile

It is the most common Healthcare-associated infection affecting an estimated 450,000 people annually in the United States alone with ~28,000 deaths from complications of this infection. This infection accounts for ~16% of all healthcare associated infections.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released February 25, 2015 by the Centers for Disease Control and Prevention CDC).

**Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections (CDI), making C. difficile a very important cause of infectious disease death in the United States alone. More than 80 percent of the deaths associated with C. difficile occurred among Americans aged 65 years or older. C. difficile causes an inflammation of the colon and deadly diarrhea.

Learn more about the C Diff Foundation at: https://cdifffoundation.org

The C Diff Foundation, a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization announced today that the Foundation will offer the first ever clinic sponsored by the C Diff Foundation and dedicated to patients diagnosed and recovering from a C. difficile infection (CDI).

Related link: https://cdifffoundation.org/

6th Annual International C.diff. Conference and Health EXPO in Philadelphia PA November 8-9

PHILADELPHIA, Pa. /ScoopCloud/ -- The C Diff Foundation is honored to welcome 20+ leading topic experts joined by Dale Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital and Mark Wilcox,B Med Sci, BM, BS, MD, FRCPath-, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds, and Lead on Clostridium difficile for Public Health England (PHE).

Dale Gerding, MD, FACP, FIDSA and Mark Wilcox, B Med Sci, BM ,BS, MD, FRCPath- will be this year's Conference Chairs of the upcoming 6th Annual International "C.diff. Awareness Conference and Health EXPO," taking place on November 8 and 9, 2018 at the Embassy Suites by Hilton Philadelphia Airport - Philadelphia, Pennsylvania.

Dale Gerding, MD, FACP, FIDSA and Mark Wilcox,B Med Sci, BM, BS, MD, FRCPath- join the internationally recognized experts in health care, academic, and industry leaders to discuss the burden of Clostridium difficile infections (C.difficile, C.diff., CDI) Prevention, Treatments, Diagnostics, Research, Clinical Trials, with Microbiome Research, Infection Prevention, Sepsis Prevention, Environmental Safety, Fecal Microbiota Restoration, Antibiotic Stewardship, Scientific Poster Presentations and more.

To learn more about this extraordinary conference, agenda and guest speakers: https://cdifffoundation.org/2018-guest-speakers/

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

All attendees will have the highest levels of peer networking and learning opportunity at the International C.diff. Awareness Conference and Health EXPO. The conference program builds in time for face-to-face interaction between attending executives, corporate representatives and industry experts exhibiting in the health expo.

Attendee Barley Chironda, Infection Control Specialist, said about the 2017 conference, "I have attended all of the C Diff Foundation Conferences and I am always in awe at the wealth of new information that is presented at each conference. As an Infection Control Specialist, and a person who deals with Healthcare Infections, I feel this conference allows great knowledge sharing and networking."

With upmost appreciation we thank the following Exhibiting Sponsors for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide:
- Diamond: Synthetic Biologics.
- Gold: Clorox Healthcare, Seres Therapeutics, ROCHE, Rebiotix, Pfizer.
- Silver: Mr. & Mrs. Angelo Ortiz.
- Bronze: Honey Bee Handiworks, Trinity Guardion, Steriliz, Safety Net America, SporeGen.

This conference is supported through an educational grant from Sanofi Pasteur US.

Visit https://cdifffoundation.org for more information. Contact Angelo Ortiz for registration, exhibiting/sponsor opportunities, and media partnerships: angelo.ortiz@cdifffoundation.org or Mobile (919) 201-1512.

About The C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide. Listen to "C.diff. Spores and More" Tuesday's at 1 p.m. ET (www.cdiffradio.com), sponsored by Clorox Healthcare, providing leading up-to-date information on topics that are in align with their mission.

Follow C Diff Foundation on LinkedIn, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2018

The C Diff Foundation is honored to welcome 20+ leading topic experts joined by Dale Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital and Mark Wilcox, B Med Sci, BM, BS, MD, FRCPath-, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT).

Related link: https://cdifffoundation.org/

C Diff Foundation Introduces Book, ‘Nutrition – Managing Meals through a C. difficile Infection’

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation announces the release of a nutritional guide, "Nutrition; Managing Meals through a C. difficile Infection" (ISBN: 978-1973304241) authored by Nancy C. Caralla, C Diff Foundation's Foundress, Executive Director and three time C. difficile Infection Survivor and co-author Karen F. Factor, MBA, RDN,CSR, LDN, C Diff Foundation Registered Dietitian during November 2017 Clostridium difficile (C. difficile, C.diff.) Infection Awareness Month.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

The book is a useful tool for patients, caregivers and clinicians to inform, educate, and guide in the nutritional challenges that can occur during and after a C. difficile infection. The importance of proper nutrition is paramount in aiding individuals diagnosed and suffering with a C. difficile infection.

Paperback and Kindle Edition available through Amazon (http://a.co/iDBSedO) and the Book Patch.

"A Clostridium difficile infection impacts each person differently. Individuals will not all experience the same nutritional and hydration challenges. This book contains educational information centered on C. difficile infection prevention, nutrition, hydration, with chapters defining probiotics, Vitamin D, and environmental safety," stated Caralla.

Fifty percent of the income generated from the sales of "Nutrition; Managing Meals through a C. difficile Infection" will be donated to the C Diff Foundation to support and grow their mission -- Educating and advocating for C. difficile infection prevention, treatments, environmental safety, and support worldwide.

"Had this information been available at the initial diagnosis of this horrific infection the devastation and dietary complications would have been avoided. This information is invaluable to patients, their families and caregivers by providing the necessary tools to manage nutrition and hydration through a C. difficile infection," stated Kathy Bischoff, C. difficile infection survivor.

About the C Diff Foundation:
The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100 percent volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide. Visit https://cdifffoundation.org/.

Media Contact:
Denise Graham
denise@cdifffoundation.org.
Mobile: (919) 201-1512

*PHOTO for Media: Send2Press.com/300dpi/17-1130s2p-cdiff-nutrition-300dpi.jpg

The C Diff Foundation announces a new nutritional guide, "Nutrition; Managing Meals through a C. difficile Infection" (ISBN: 978-1973304241) authored by Nancy C. Caralla, C Diff Foundation's Foundress, Executive Director and three time C. difficile Infection Survivor and co-author Karen F. Factor, MBA, RDN,CSR, LDN, C Diff Foundation Registered Dietitian during November 2017 Clostridium difficile Infection Awareness Month.

Related link: https://cdifffoundation.org/

C Diff Foundation Knocks on Governor’s Doors Nationwide to Proclaim the Month of November for Clostridium difficile Infection Awareness

NEW PORT RICHEY, Fla. /ScoopCloud/ -- C Diff Foundation welcomes November as Clostridium difficile Awareness Month and it is an exciting time for patients, families, clinicians, and organizations. Governors in several states honor our efforts by signing proclamations declaring November to be Clostridium difficile Awareness Month in their states.

These proclamations are available to you and can be downloaded for your use from our website: https://cdifffoundation.org/make-a-difference-november/.

This year, our goal is to obtain proclamations in all 50 states. Denise Graham, Strategic Advisor of the C Diff Foundation, proudly leads the Clostridium difficile (C. diff., C. difficile) State Proclamation effort.

Join us at the upcoming 5th Annual International C.diff. Awareness Conference and Health EXPO, taking place on November 9 and 10, 2017 at the University of Nevada - Las Vegas, Thomas and Mack Center, 2nd Floor Pavilion, Las Vegas, Nevada.

Complimentary registrations are available: https://cdifffoundation.org/registration/

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

Dale Gerding, MD, FACP, FIDSA joins 25+ internationally recognized experts in health care, academic, and industry leaders to discuss the burden of Clostridium difficile infections (C.difficile, C.diff., CDI) and prevention, treatments, diagnostics, research, clinical trials, with Microbiome research, Infection Prevention, Irritable Bowel Syndrome treatments and clinical trials, Environmental Safety, Fecal Microbiota Restoration, Antibiotic Stewardship and more.

To learn more about the program and guest speakers: https://cdifffoundation.org/cdiff2017guest-speakers/

Attendee Linda Jablonski, RN, BSN said about the 2016 conference, "The information shared at the conference provided up-to-date studies and important information that help us all save lives."

Visit https://cdifffoundation.org for more information. Contact Denise Graham for registration and media inquiries desinse@cdifffoundation.org or Mobile (202)-294-6314.

About the C Diff Foundation:
The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#Cdiff2017

Media Contact:
Denise Graham
denise@cdifffoundation.org

*IMAGE for media: Send2Press.com/300dpi/17-0928s2p-cdiff-awareness-300dpi.jpg

C Diff Foundation welcomes November as Clostridium difficile Awareness Month and it is an exciting time for patients, families, clinicians, and organizations. Governors in several states honor our efforts by signing proclamations declaring November to be Clostridium difficile Awareness Month in their states.

Related link: https://cdifffoundation.org/

The C Diff Foundation Selected to Receive JL Simmons NonProfit PR Grant for 2016

NEW PORT RICHEY, Fla., March 31, 2016 (SEND2PRESS NEWSWIRE) -- The C Diff Foundation announces that it has been selected to receive the annual J.L. Simmons NonProfit PR Grant for 2016. Each year the PR Grant, launched in 2000 by Neotrope, helps selected worthy causes raise visibility to media and public for the charity's good works.

"Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year. With annual fatalities close to 29,000 a year, it's a global problem that affects every community," explains Nancy Caralla, Executive Director and Founder of the C Diff Foundation. "With the support of companies like Neotrope, we can further raise C. diff. awareness and save lives worldwide."

With this commitment, Neotrope(R) aligns itself with the C Diff Foundation to help awareness through education about research being conducted by the government, industry, and academia; and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

As part of this in-kind grant program, Neotrope is providing public relations (PR) solutions, news dissemination (through its Send2Press(R) Newswire service), online advertising, and social media marketing for the C Diff Foundation. This program is intended to help raise awareness of the 501(c)(3) nonprofit to traditional media, to the public, as well as potential sponsors and donors, regarding their efforts.

"We're honored to be helping the C Diff Foundation with their health-oriented charitable endeavors over the coming year," said Neotrope CEO, Christopher Laird Simmons; a member of PRSA and ASCAP. "The C Diff Foundation now speaks for the thousands of patients within the United States who are diagnosed with a C. diff. infection each year."

About the C Diff Foundation:

The C Diff Foundation is a nonprofit 501(c)(3) organization, established in 2012 and dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, and environmental safety worldwide. The Foundation's founder is a nurse and after suffering through C. difficile infections herself and witnessing the loss of her father, whose life was claimed by C. difficile involvement, the C Diff Foundation came to fruition.

The C Diff Foundation, with their Volunteer Patient Advocates, successfully "Raise C. diff. Awareness" nationwide and in 38 countries, and host a Nationwide information Hot-Line (1-844-FOR-CDIF) which also supports health care providers and patients to manage through the difficulties of a C. diff. infection. Learn more at: http://cdifffoundation.org/.

About the NonProfit PR Grant:

The NonProfit PR Grant(TM) program was originally launched in 2000 to help assist U.S. 501(c)(3) worthy causes to raise awareness, attract halo sponsors, and better connect with donors and volunteers. Other PR industry firms have since copied the name, but ours is the original.

Starting in 2013, the Grant was re-named after the company co-founder, the late Dr. J.L. Simmons, PhD, who passed away in 2003. Now the Neotrope PR Grant program is known as the "J.L. Simmons NonProfit PR Grant."

With this cause-related marketing grant program, Neotrope has been honored to help many worthy causes in past years, including the Bob Moog Foundation, Camp Blue Skies, Children Awaiting Parents, Girls Write Now, Move for Hunger, National Inclusion Project, Pacific Pinball Museum, Special Equestrians, Starlight Children's Foundation, World Savvy and dozens more (use of any org name does not imply endorsement).

Additional information regarding the Neotrope 2016 J.L. Simmons NonProfit PR Grant program for U.S. charitable nonprofits and grant recipients can be found at: http://prgrants.com/ or on Facebook at https://www.facebook.com/NonProfitPRGrants.

About Neotrope:

Since 1983 Neotrope(R) has delivered services to raise organization awareness including brand identity, marketing, public relations (PR), web development and ecommerce, and Last Mile SEO(TM) services. Neotrope is also an entertainment publishing company involved in books, music, software, and online magazines. The company, co-founded by Dr. J.L. Simmons, and Christopher Laird Simmons, has been at the forefront of many communication and technology movements for over three decades. Neotrope was an Inc. 5000 company in 2009. More information: http://Neotrope.com.

* IMAGE for media: Send2Press.com/mediaboom/15-1022-cdiff-ribbons-300dpi.jpg

* LOGO for media: Send2Press.com/mediaboom/15-0723-cdiff-fdn-300dpi.jpg

Twitter: @cdiffFoundation #cdiff2015 @prgrants #prgrant

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/the-c-diff-foundation-selected-to-receive-jl-simmons-nonprofit-pr-grant-for-2016-2016-0331-02.shtml.

NEWS SOURCE C Diff Foundation :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2016 Send2Press® Newswire, a service of Neotrope®.